$CARM
Carisma Therapeutics Inc

2019 Q1 Form 10-Q Financial Statement

#000148500319000029 Filed on May 10, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.060M $1.950M
YoY Change 56.92% -11.76%
% of Gross Profit
Research & Development $4.686M $3.255M
YoY Change 43.96% 13.26%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K
YoY Change 0.0% -37.5%
% of Gross Profit
Operating Expenses $6.741M $4.007M
YoY Change 68.23% -39.17%
Operating Profit -$6.741M -$4.007M
YoY Change 68.23% -34.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $261.0K $44.00K
YoY Change 493.18% -56.44%
Pretax Income -$6.480M -$3.960M
YoY Change 63.64% -34.65%
Income Tax
% Of Pretax Income
Net Earnings -$6.480M -$3.963M
YoY Change 63.51% -34.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$0.08 -$111.0K
COMMON SHARES
Basic Shares Outstanding 77.46M shares 43.11M shares
Diluted Shares Outstanding 77.46M shares

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.40M $19.70M
YoY Change 115.23% -2.96%
Cash & Equivalents $42.44M $19.69M
Short-Term Investments
Other Short-Term Assets $3.000M $600.0K
YoY Change 400.0% -14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.45M $20.33M
YoY Change 123.61% -3.12%
LONG-TERM ASSETS
Property, Plant & Equipment $272.0K $473.0K
YoY Change -42.49% -33.75%
Goodwill $13.06M $13.06M
YoY Change 0.0% -22.53%
Intangibles $46.40M $46.40M
YoY Change 0.0% -23.31%
Long-Term Investments
YoY Change
Other Assets $232.0K $19.00K
YoY Change 1121.05%
Total Long-Term Assets $59.99M $59.97M
YoY Change 0.04% -23.21%
TOTAL ASSETS
Total Short-Term Assets $45.45M $20.33M
Total Long-Term Assets $59.99M $59.97M
Total Assets $105.4M $80.29M
YoY Change 31.32% -18.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.683M $1.393M
YoY Change 20.82% 14.74%
Accrued Expenses $5.234M $3.853M
YoY Change 35.84% 103.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.053M $5.246M
YoY Change 34.45% 62.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $398.0K $260.0K
YoY Change 53.08% -99.44%
Total Long-Term Liabilities $398.0K $260.0K
YoY Change 53.08% -99.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.053M $5.246M
Total Long-Term Liabilities $398.0K $260.0K
Total Liabilities $7.451M $5.506M
YoY Change 35.33% -91.68%
SHAREHOLDERS EQUITY
Retained Earnings -$192.5M -$156.3M
YoY Change 23.16% 20.79%
Common Stock $77.00K $43.00K
YoY Change 79.07% 72.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.06M $23.86M
YoY Change
Total Liabilities & Shareholders Equity $105.4M $80.29M
YoY Change 31.32% -18.95%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$6.480M -$3.963M
YoY Change 63.51% -34.61%
Depreciation, Depletion And Amortization $50.00K $50.00K
YoY Change 0.0% -37.5%
Cash From Operating Activities -$7.992M -$4.383M
YoY Change 82.34% -15.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K
YoY Change -100.0% -87.5%
Cash From Investing Activities $0.00 $5.000K
YoY Change -100.0% -93.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $9.376M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.000K $9.386M
YoY Change -99.93% 20757.78%
NET CHANGE
Cash From Operating Activities -$7.992M -$4.383M
Cash From Investing Activities $0.00 $5.000K
Cash From Financing Activities $7.000K $9.386M
Net Change In Cash -$7.985M $5.008M
YoY Change -259.44% -198.7%
FREE CASH FLOW
Cash From Operating Activities -$7.992M -$4.383M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77464781 shares
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Sesen Bio, Inc.
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Trading Symbol
TradingSymbol
SESN
CY2018Q1 ebio Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
CY2018Q1 ebio Class Of Warrant Or Right Price Per Share
ClassOfWarrantOrRightPricePerShare
0.125
CY2018Q1 ebio Stock Issued During Period Exercise Of Warrants Value
StockIssuedDuringPeriodExerciseOfWarrantsValue
336000 USD
CY2018Q1 ebio Stock Issued During Period Shares Exercise Of Warrants
StockIssuedDuringPeriodSharesExerciseOfWarrants
420778 shares
CY2019Q1 ebio Working Capital Net
WorkingCapitalNet
38400000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1367000 USD
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1683000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4746000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5234000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
464000 USD
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
519000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230154000 USD
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230487000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
401000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
326000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
211000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000 USD
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20250354 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14946194 shares
CY2018Q4 us-gaap Assets
Assets
111561000 USD
CY2019Q1 us-gaap Assets
Assets
105439000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
51756000 USD
CY2019Q1 us-gaap Assets Current
AssetsCurrent
45451000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14690000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19698000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50442000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42457000 USD
CY2018Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1200000 USD
CY2019Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1000000 USD
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
48400000 USD
CY2019Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
47400000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50422000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42400000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42437000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5008000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7985000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
420778 shares
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77456180 shares
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77464781 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77456180 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77464781 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
77000 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
77000 USD
CY2018Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
2928000 USD
CY2019Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
3542000 USD
CY2019Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2019Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
49000 USD
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
49000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1045000 USD
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
491000 USD
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 USD
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1952000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3055000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
13064000 USD
CY2019Q1 us-gaap Goodwill
Goodwill
13064000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
316000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
85000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
709000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
236000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1912000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2019Q1 us-gaap Lease Cost
LeaseCost
151000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
232000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
116000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
116000 USD
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111561000 USD
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105439000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6113000 USD
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7053000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9386000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4383000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7992000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3963000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6480000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
261000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
4007000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6741000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4007000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6741000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
75000 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
211000 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
136000 USD
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75000 USD
CY2018Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
0 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
38202000 USD
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000 USD
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
272000 USD
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
232000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
136000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
313000 USD
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
398000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
261000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1334000 USD
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3014000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9376000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2018Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10000 USD
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
7000 USD
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3255000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4686000 USD
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
20000 USD
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
20000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
20000 USD
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
20000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186024000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192500000 USD
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192504000 USD
CY2019Q1 us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
236480000 USD
CY2018Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
9000000 USD
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
7968128 shares
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.13
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
326000 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1076840 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.13
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
363500 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
650000 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
425000 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2110115 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3941947 shares
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5688562 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.12
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.62
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.44
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.85
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
76000 USD
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9040000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18034000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
23858000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
44207000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
38060000 USD
CY2018Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
278000 USD
CY2019Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
610000 USD
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35674000 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77458000 shares

Files In Submission

Name View Source Status
0001485003-19-000029-index-headers.html Edgar Link pending
0001485003-19-000029-index.html Edgar Link pending
0001485003-19-000029.txt Edgar Link pending
0001485003-19-000029-xbrl.zip Edgar Link pending
ebio-20190331.xml Edgar Link completed
ebio-20190331.xsd Edgar Link pending
ebio-20190331_cal.xml Edgar Link unprocessable
ebio-20190331_def.xml Edgar Link unprocessable
ebio-20190331_lab.xml Edgar Link unprocessable
ebio-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glenmacdonaldebioemploym.htm Edgar Link pending
glenmacdonaldebioemploym001.jpg Edgar Link pending
glenmacdonaldebioemploym002.jpg Edgar Link pending
glenmacdonaldebioemploym003.jpg Edgar Link pending
glenmacdonaldebioemploym004.jpg Edgar Link pending
glenmacdonaldebioemploym005.jpg Edgar Link pending
glenmacdonaldebioemploym006.jpg Edgar Link pending
glenmacdonaldebioemploym007.jpg Edgar Link pending
glenmacdonaldebioemploym008.jpg Edgar Link pending
glenmacdonaldebioemploym009.jpg Edgar Link pending
glenmacdonaldebioemploym010.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sesn-033119x10q.htm Edgar Link pending
sesn-033119x311.htm Edgar Link pending
sesn-033119x312.htm Edgar Link pending
sesn-033119x321.htm Edgar Link pending
Show.js Edgar Link pending